Toro-Montecinos M, Ballescá F, Ferrandiz C, Teniente-Serra A, Martinez-Caceres E, Carrascosa J M
a Department of Dermatology , Hospital Universitario Germans Trias i Pujol , Barcelona , Spain.
b Departamento de Medicina , Universidad Autònoma de Barcelona , Barcelona , Spain.
J Dermatolog Treat. 2019 Feb;30(1):35-39. doi: 10.1080/09546634.2018.1468065. Epub 2018 May 10.
Monitoring serum drug levels has been proposed as a useful tool for improving and personalizing the management of psoriasis. However, in the case of ustekinumab the usefulness of such monitoring was not demonstrated when drug levels were measured at week 12.
To evaluate the correlation of serum ustekinumab levels measured at weeks 6 and 12 with clinical response.
In a prospective cohort study, we enrolled patients with psoriasis treated with ustekinumab 45 mg every 12 weeks for at least 24 weeks. We measured serum ustekinumab levels at weeks 6 and 12 in each patient. Using the absolute PASI score, response to treatment was defined as optimal (≤1), excellent (≤3), appropriate (>3 and ≤5), or inappropriate (>5).
About 54 serum samples from 27 patients were analyzed. No correlation was found between serum drug levels and absolute PASI at week 12. At week 6, an inverse linear correlation was found (p = .0001). Moreover, serum levels at week 6 were higher in patients with optimal, excellent and appropriate responses than in patients with an inappropriate response.
Assessment of ustekinumab serum levels at week 6 could provide useful information in routine clinical practice.
监测血清药物水平已被提议作为改善银屑病管理并使其个性化的一种有用工具。然而，对于优特克单抗而言，在第12周测量药物水平时，并未证明这种监测的有用性。
评估在第6周和第12周测得的血清优特克单抗水平与临床反应之间的相关性。
在一项前瞻性队列研究中，我们纳入了接受优特克单抗治疗（每12周45mg，至少治疗24周）的银屑病患者。我们测量了每位患者在第6周和第12周时的血清优特克单抗水平。使用绝对PASI评分，将治疗反应定义为最佳（≤1）、优秀（≤3）、合适（>3且≤5）或不合适（>5）。
分析了来自27名患者的约54份血清样本。在第12周时，未发现血清药物水平与绝对PASI之间存在相关性。在第6周时，发现呈负线性相关（p = 0.0001）。此外，最佳、优秀和合适反应患者在第6周时的血清水平高于反应不合适的患者。
在第6周评估优特克单抗血清水平可为常规临床实践提供有用信息。
